From our survey

How people really choose depression treatment in St. Charles

Assumptions about how people find mental health care are cheap to hold and expensive to act on. We tested several of ours against a survey of 443 adults in ten Midwest states, and a few came back to us broken.

Here are six beliefs that circulate in St. Charles and everywhere else, checked against what respondents said. Every figure is from the panel's validated data.

Myth one: people discover these treatments through advertising

They may discover them that way; they do not decide that way. When we asked whose recommendation would really push them toward ketamine-based care, 74 percent of respondents chose their own doctor. Ads drew 2 percent, podcast hosts 1. A close friend or relative pulled 18 percent, and a uniformed figure followed online pulled 4.

A billboard on a commute through St. Charles County can make a treatment name familiar, but the decision still happens across a desk from someone holding your chart. Treating awareness and persuasion as one job confuses the first leg of the relay with the finish.

Myth two: by now, most people know what Spravato is

Respondents were blunt: 73 percent had no familiarity with it at all, 21 percent more recognized the word but not the medicine, and 6 percent could say what the drug does.

Spravato is esketamine in nasal spray form. Its clearance from the FDA is for treatment-resistant depression, and it is dosed only in certified offices, where patients stay for a monitored stretch afterward. It is not ketamine mailed home by an online prescriber, nor an infusion clinic's off-label protocol. If nearly three quarters of the public has never met the word, the distinctions underneath it are even less familiar, which is a reason to ask which version is meant, not a reason to feel uninformed. Brain Recovery Centers keeps a plain description of its Spravato treatment for anyone who wants the approved version spelled out.

Myth three: depression that resists medication is an edge case

Looking at their own circles, 72 percent of respondents had seen standard treatment fail to clear depression, anxiety, or PTSD: The experience was personal for 37 percent, belonged to someone close for 22 percent, and was both for 13 percent; 28 percent had none.

Clinical writing tends to describe treatment resistance as a subgroup. In a general sample, nearly three households in four had direct contact with it, so someone raising it at their next appointment is not raising anything exotic.

Myth four: people will pay out of pocket to skip the red tape

Some will; most will not. We put the tradeoff directly: covered care with more hoops, or paying yourself and starting faster. Half chose the hoops, 23 percent chose to pay, and 26 percent were unsure.

The surrounding numbers say it louder. Coverage topped the list of provider factors; 85 percent of respondents put it in their leading pair; proximity trailed at 43, FDA approval sat at 27, quick results at 24, discretion at 11, and service-member expertise at 10. Whether to pursue treatment at all would turn heavily on insurance for 65 percent; it was somewhat important for 21 percent and irrelevant for 14. Payment is not a detail sorted out later. For most people it is the gate.

Myth five: everybody wants it at home

Convenience did not win. Among respondents, 44 percent preferred in-person clinic care, while home telehealth drew 22 percent and a start-at-clinic sequence 23 percent, and 11 percent were indifferent. For a treatment people barely know, being watched by staff may read as safety rather than hassle, and a clinic within reasonable driving distance is not an outdated format here; proximity was a top-two consideration for 43 percent.

Myth six: the public is hostile to the idea

The public is mostly undecided, which is different. Asked for a gut reaction to ketamine as a depression or PTSD treatment, 34 percent of respondents chose cautious but open, while 18 percent felt hopeful or curious; the remainder broke into skeptics (21 percent), people new to the idea (18 percent), and a negative 9 percent. That makes 51 percent receptive and 9 percent firmly opposed. Skepticism here is usually a request for information, and the information people want is specific: 59 percent told us FDA approval would decide or heavily sway them.

A bonus myth: people search using the drug name

They do not. Our open-text question asked what exact words respondents would type to find help, and 319 of them answered with symptoms and appeals such as "someone please help me," "depressed," and "help with ptsd." People start not by comparing protocols but by trying to describe a weight they have carried and find someone who deals with it.

What to do with all this

If you are in the St. Charles area and this sounds like your situation, the sequence this data supports is unglamorous. Get an appointment with a physician and say plainly that medication has not been enough. Bring your medication history in writing. Ask whether you meet the criteria, and which version of this treatment is being described. Call your insurer about prior authorization before calling any clinic about availability.

This article reports research about decisions, not clinical evidence, and it is not medical advice or a recommendation of any treatment. Whether a therapy suits you is for a clinician familiar with your full history.

Please take this last part seriously. If depression has led you to think about ending your life, that justifies dropping everything else. A trained Lifeline counselor picks up at 988, by phone or text, free, whatever the hour. Telling someone what is happening is the strongest move you have right now.

Methodology

We commissioned this study as the site's publisher and funded it. Pollfish ran it on its consumer panel until the survey closed on June 23, 2026. The 443 completed responses came from the general public, ages 18 through 64, across a ten-state Midwest region, and every respondent passed a consent screener; this was not a recruited patient group. Several questions allowed multiple selections, so their totals run past 100. All numbers follow the panel's completed validation.